Biotech entity
Across an 86-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 2. The clearest coverage concentration is pharma: 3 of 4 stories, with the rest divided among 1 other category. Their average consequence score of 5.3 runs below the beat's 6.3 for that window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Across an 86-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 2. The clearest coverage concentration is pharma: 3 of 4 stories, with the rest divided among 1 other category. Their average consequence score of 5.3 runs below the beat's 6.3 for that window. Of the tracked stories, 1 of 4 also mention Avis Budget Group, the most common co-covered peer. They are better corroborated than the beat average, carrying 3.3 original sources each against 3.2 for the same window. This profile follows 4 Biotech stories mentioning Pomerantz LLP across the period from March 22, 2026 to June 15, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 79 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pomerantz LLP. Shared-story counts are live from our verified record — not editorial picks.
Lead Plaintiff Deadline
Expected deadline for shareholders to petition the court to serve as lead plaintiff in the case.
Follow-up Disclosure
Secondary announcements highlight the filing and the process for shareholders to join the litigation.
Class Action Announcement
Pomerantz LLP first alerts investors to the class action filing against Boston Scientific.
Litigation Filed
Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
Partnership Termination
BMS and Nektar officially end their global clinical development collaboration.
Phase 3 Failure
Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.
BMS Partnership
Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin.
A $31.3 million impairment on the Fabric Genomics deal has drawn a securities lawsuit against GeneDx. For biotech investors, the case highlights the perils of overvalued AI acquisitions in genomics, as GeneDx trimmed its revenue forecast by up to $80 million.
Pomerantz LLP has initiated a class action lawsuit against Boston Scientific (BSX), alleging potential violations of federal securities laws. The litigation centers on the company's disclosures during a period of significant expansion and product integration, marking a critical legal challenge for the medical device giant.
Pomerantz LLP has issued a formal reminder regarding a class-action lawsuit filed against Mereo BioPharma Group plc, alleging potential violations of federal securities laws. The legal action focuses on whether the company made misleading statements or failed to disclose material facts regarding its clinical operations and financial outlook.
Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
Pomerantz LLP is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
